• Celgene International Sarl, of Boudry, Switzerland, a subsidiary of Celgene Corp., said it will request a re-examination of the negative opinion from the European Committee for Medicinal Products for Human Use (CHMP) regarding Istodax (romidepsin) for the treatment of relapsed or refractory peripheral T-cell lymphoma (PTCL). Read More
LONDON – Malignant melanoma cells manage to inactivate the tumor suppressor protein, p53, by a mechanism that has, until now, remained a mystery. Read More
DUBLIN, Ireland – Attempts to force through cuts to embryonic stem cell funding in the European Union's (EU) next five-year R&D program, due to get under way in 2014, will be strongly resisted, according to the EU Research Commissioner Máire Geoghegan-Quinn. Read More
DUBLIN, Ireland – Now that the great carnival that is the Euroscience Open Forum (ESOF) has folded its tent and set a course for Copenhagen, Denmark, it is clear that the event – the biggest ever general scientific meeting in Ireland – marks a turning point in the country's maturing engagement with research. Read More
LONDON – Cell therapy specialist Cell Medica Ltd. has raised £17 million (US$26.5 million) in a mixture of public and private funding, including a grant from the Cancer Prevention and Research Institute of Texas (CPRIT) to be devoted to setting up manufacturing and running a clinical trial in the state. Read More
LONDON – Long-awaited proposals to streamline the process of getting permission for multinational clinical trials – and halt the flight of clinical research from Europe – have been published by the European Commission. Read More
